Re:Ozempic drug supresses desire to smoke, drink and more
by reaperman on Saturday May 20, 2023 @12:04AM
(#36009286)
On the contrary: GLP1 agonists show broad health benefits across the board.
Check this 24-month clinical trial with >3000 participants[0]. It showed improvements in rates of:
- Cardiovascular death
- Non-fatal Myocardial Infarction
- Non-fatal Stroke
- Revascularisation
- HbA1c
- Fasting Plasma Glucose
- Body Weight
- Lipid Profile ( total cholesterol, LDL cholesterol and triglycerides)
- Urinary Albumin to Creatinine Ratio
- Systolic blood pressure (mmHg)
- "overall health related quality of life namely bodily pain, general health, mental component summary, mental health, physical component summary, physical functioning, role-emotional, role-physical, social functioning and vitality." (each of these categories were "quantitatively" measured using a calibrated questionnaire - - and they all showed a dose-response relationship -- 1.0mg semaglutide made a bigger improvement than 0.5 mg, vs. two different placebos)
Check this 24-month clinical trial with >3000 participants[0]. It showed improvements in rates of:
- Cardiovascular death
- Non-fatal Myocardial Infarction
- Non-fatal Stroke
- Revascularisation
- HbA1c
- Fasting Plasma Glucose
- Body Weight
- Lipid Profile ( total cholesterol, LDL cholesterol and triglycerides)
- Urinary Albumin to Creatinine Ratio
- Systolic blood pressure (mmHg)
- "overall health related quality of life namely bodily pain, general health, mental component summary, mental health, physical component summary, physical functioning, role-emotional, role-physical, social functioning and vitality." (each of these categories were "quantitatively" measured using a calibrated questionnaire - - and they all showed a dose-response relationship -- 1.0mg semaglutide made a bigger improvement than 0.5 mg, vs. two different placebos)
0: https://clinicaltrials.gov/ct2/show/results/NCT01720446?term...